Table 2.
| Immune profiles (Median) | ALL patients (n = 95) | With active malignancy (n = 19) | Without active malignancy (n = 76) | p |
|---|---|---|---|---|
| IL-6 | ||||
| D1 (pg/uL) | 52.0 (96.7) | 85.1 (291.4) | 51.3 (93.5) | 0.302 |
| D3/D1 (%) | 0.6 (0.8) | 0.8 (0.9) | 0.6 (0.7) | 0.129 |
| IL-10 | ||||
| D1 (pg/uL) | 16.7 (56.3) | 34.0 (68.0) | 15.1 (52.9) | 0.040 |
| D3/D1 (%) | 0.9 (0.6) | 0.8 (1.1) | 0.9 (0.6) | 0.649 |
| G-CSF | ||||
| D1 (pg/uL) | 70.9 (117.9) | 89.5 (357.4) | 70.8 (103.2) | 0.827 |
| D3/D1 (%) | 0.6 (0.8) | 1.5 (1.9) | 0.6 (0.7) | 0.004 |
| TNF-α | ||||
| D1 (pg/uL) | 33.5 (45.2) | 44.6 (87.0) | 32.6 (40.8) | 0.220 |
| D3/D1 (%) | 0.9 (0.5) | 0.9 (0.4) | 0.9 (0.5) | 0.405 |
| HLA-DR | ||||
| D1 (%) | 92.3 (16.0) | 91.6 (11.6) | 92.6 (17.2) | 0.487 |
| D3/D1 (%) | 1.0 (0.1) | 0.9 (0.1) | 1.1 (0.1) | 0.508 |
Abbreviations: G-CSF, granulocyte colony-stimulating factor; HLA-DR: human leukocyte antigen D—related; IL, interleukin; TNF: tumor necrosis factor.